Propiedad y actividad de insiders de Harvard Bioscience, Inc. (HBIO): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $7.97 |
| Capitalización | $36M |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-06-09 | Eade Katherine A. | A-Award | 16,556 | |
| 2026-06-09 | Snider William | A-Award | 16,556 | |
| 2026-06-09 | DENELSKY STEPHEN J | A-Award | 16,556 | |
| 2026-06-09 | Gagnon Robert E. | A-Award | 16,556 | |
| 2026-06-09 | Benson Seth Benjamin | A-Award | 16,556 | |
| 2026-03-20 | Frost Mark T | A-Award | 30,000 | |
| 2026-03-16 | Frost Mark T | P-Purchase | 5,000 | $25K |
| 2026-03-20 | Duke John D | A-Award | 75,000 | |
| 2026-03-17 | DENELSKY STEPHEN J | P-Purchase | 10,000 | $49K |
| 2026-03-17 | Snider William | P-Purchase | 8,475 | $41K |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $5.6M | $5.7M | $8.2M | $8.3M | $8.3M | $7.8M | $4.5M | $4.3M | $4.1M | $8.6M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $19.9M | $17.1M | $21.5M | $20.7M | $17.8M | $21.8M | $16.7M | $16.1M | $14.9M | $16.0M |
| Inventario | $20.0M | $21.4M | $25.1M | $22.1M | $22.3M | $27.6M | $26.4M | $24.7M | $23.2M | $20.8M |
| Activos Corrientes | $45.5M | $47.5M | $54.7M | $53.6M | $51.7M | $61.6M | $51.1M | $49.0M | $45.1M | $48.2M |
| Inmovilizado Material | $4.3M | $4.1M | $5.9M | $13.2M | $11.7M | $10.3M | $9.2M | $8.8M | $11.2M | $4.8M |
| Fondo de Comercio | $38.0M | $40.0M | $57.3M | $57.4M | $58.6M | $57.7M | $56.3M | $57.1M | $56.3M | $9.6M |
| Activos Intangibles | $18.7M | $17.2M | $45.8M | $38.4M | $33.2M | $27.4M | $21.0M | $16.0M | $11.1M | $7.6M |
| Activos Totales | $107.8M | $109.4M | $168.1M | $164.9M | $156.3M | $162.3M | $145.4M | $137.4M | $126.6M | $80.1M |
| Cuentas por Pagar | $6.2M | $4.4M | $7.4M | $5.3M | $6.0M | $4.9M | $6.4M | $5.6M | $4.8M | $3.7M |
| Deuda a Corto | $2.4M | $2.8M | $2.0M | $6.9M | $1.7M | $3.2M | $3.8M | $5.9M | $37.0M | $1.5M |
| Pasivos Corrientes | $14.6M | $14.0M | $21.5M | $25.3M | $21.1M | $25.3M | $23.2M | $26.5M | $55.0M | $22.0M |
| Deuda a Largo | $11.4M | $9.0M | $58.8M | $46.9M | $46.3M | $45.1M | $43.0M | $30.7M | 0 | $35.9M |
| Pasivos Totales | $35.6M | $28.5M | $85.9M | $83.2M | $79.6M | $78.9M | $73.1M | $64.3M | $63.3M | $66.3M |
| Reservas | -$116.0M | -$117.0M | -$119.9M | -$124.6M | -$132.4M | -$132.7M | -$142.2M | -$145.6M | -$158.0M | -$214.7M |
| Patrimonio Neto | $72.2M | $80.9M | $82.2M | $81.7M | $76.7M | $83.4M | $72.2M | $73.1M | $63.3M | $13.7M |
| Deuda Total | $13.7M | $11.7M | $60.8M | $64.5M | $57.6M | $57.0M | $54.2M | $42.8M | $44.5M | $44.3M |
| Deuda Neta | $8.2M | $6.0M | $52.6M | $56.1M | $49.3M | $49.1M | $49.7M | $38.5M | $40.4M | $35.7M |
| Capital Circulante | $30.9M | $33.5M | $33.2M | $28.3M | $30.6M | $36.3M | $27.9M | $22.5M | -$9.8M | $26.3M |
Salud financiera
| Deuda / Patrimonio | 5.96 |
| Ratio corriente | 1.87 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.04 |
Rentabilidad
| Rentabilidad sobre capital | -92.01% |
| Rentabilidad sobre capital invertido | 1.91% |
| Rentabilidad sobre activos | -13.65% |
| Margen bruto | 58.16% |
| Margen operativo | 1.17% |
| Margen neto | -11.86% |
Empresas relacionadas: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explorar sector: Healthcare · Medical - Instruments & Supplies
Más secciones de HBIO: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones